Eckert & Ziegler awards grants to young researchers in nuclear medicine

Berlin, October 13, 2010. This year's travel grants from Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) have been awarded to five nuclear medicine scientists from Australia, Germany, the Netherlands and the United States. The prize-winners were selected by a jury from the European Association of Nuclear Medicine (EANM) from a total of 534 entries. Work in the fields of oncologic and neurological diagnostic received recognition. The travel grants, which amount to 1,000 EUR each, were presented today at the annual congress of the EANM in Vienna to:

M. Mustafa, Germany: The impact of SPECT/CT hybrid imaging in detecting regional lymph node involvement in T1 papillary thyroid carcinoma: presenting an update on a bicentric study including 202 patients N. Zarzhevsky, United States: White Matter Lesions augment Cognitive Impairments of Dopaminergic Denervation of the Caudate Nucleus in Parkinson disease T. Aukema, Netherlands: 18F-FDG PET/CT and diagnostic CT for the prediction of histopathologic treatment response after epidermal growth factor receptor tyrosinekinase inhibitor treatment in patients with resectable NSCLC J. Beauregard, Australia: The tumoural "Sink Effect" on the biodistribution of 68Ga-octreotate: implications for peptide receptor radionuclide therapy L. Vivash, Australia: The Development of [18F]-Flumazenil-PET for Localisation of the Epileptogenic Zone in Patients with Medically Refractory Focal Epilepsy

"The Positron Emission Tomography (PET) imaging technique is the fastest growing segment on the medical device market. In presenting the 'EANM Eckert & Ziegler Abstract Award' we wish to encourage young researchers to present their ideas to a wider audience and to collaborate more in exchanging ideas with other researchers engaged in the field of nuclear medicine. We hope that this will help to ensure that the enormous progress which has been made in medical imaging can soon be transformed into more precise, faster or cheaper methods of diagnosis and therapy," explained Dr. Andreas Eckert, CEO of Eckert & Ziegler.

Eckert & Ziegler AG is one of the world's largest providers of isotope component technology for radiation therapy and nuclear medicine. The Berlin based company has 540 employees and is listed at the Frankfurt Stock exchange. You can find further information about the Eckert & Ziegler travel grant at www.ezag.de/en/award_e.html.

The Board of Directors